Vir Biotechnology to receive EUR 55 million initial reimbursement payment upon closing, and up to EUR 495 million in clinical, regulatory and sales milestones, along with tiered, mid-teen to high-twenties percent royalties on net sales Companies to share clinical development costs for ongoing ECLIPSE registrational program with Norgine contributing approximately 25% of go-forward external costs ECLIPSE 3, designed to support... Read More

SAN FRANCISCO / Nov 19, 2025 / Business Wire / Vir Biotechnology, Inc . (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3 at 10:50 a.m. ET / 7:50 a.m. PT in Miami, Florida. A live webcast of the presentation will be made available under Events & Presentations in the... Read More

SOLSTICE trial data demonstrate that 66% of chronic hepatitis delta participants receiving a monthly dose of tobevibart and elebsiran achieved undetectable HDV RNA at Week 48 Combination well-tolerated: No grade 3 or higher treatment-related adverse events and no treatment-related discontinuations ECLIPSE registrational program evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta fully underway,... Read More

SAN FRANCISCO / Nov 07, 2025 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 2:00 p.m. GMT / 9:00 a.m. ET / 6:00 a.m. PT in London, United Kingdom. A live webcast of the presentation will be made available under Events & Presentations in the... Read More

ECLIPSE 1 enrollment completed approximately two months ahead of schedule; ECLIPSE 2 and ECLIPSE 3 progressing with strong enrollment momentum, with topline data for all three studies expected in the first quarter of 2027 Comprehensive data update for VIR-5500, a PSMA-targeting PRO-XTEN ® dual-masked T-cell engager, planned for the first quarter of 2026 First patient dosed in Phase 1 study of VIR-5500 in combination with... Read More

ECLIPSE 1 estimated date of last participant reaching primary endpoint (primary completion) in the fourth quarter of 2026, and topline data expected in the first quarter of 2027 ECLIPSE registrational program on target, with ECLIPSE 2 and 3 enrolling well and in line with the Company’s expectations Swift recruitment underscores high unmet medical need for effective and convenient chronic hepatitis delta treatment SAN... Read More

SAN FRANCISCO / Oct 22, 2025 / Business Wire / Vir Biotechnology, Inc . (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2025, on November 5, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on November 5, 2025. The corporate update and financial results will be provided via a press release... Read More

Phase 1 clinical trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 in combination with androgen receptor pathway inhibitors in first-line mCRPC Clinical trial builds on encouraging Phase 1 data of monotherapy VIR-5500 in late-line patients presented in January 2025 SAN FRANCISCO / Oct 09, 2025 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first... Read More

Week 48 endpoint results from the SOLSTICE Phase 2 clinical study evaluating tobevibart alone or in combination with elebsiran for chronic hepatitis delta to be presented Vir Biotechnology to showcase progress in hepatitis delta clinical efforts with one oral and one poster presentation SAN FRANCISCO / Oct 07, 2025 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present Week 48... Read More

SAN FRANCISCO / Aug 25, 2025 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 23 rd Annual Global Healthcare Conference on Tuesday, September 9 at 1:05 p.m. PT / 4:05 p.m. ET in New York, New York. A live webcast of the fireside chat will be made available under Events &... Read More

ECLIPSE registrational program in chronic hepatitis delta fully underway First patient dosed in Phase 1 study of VIR-5525, an EGFR-targeting PRO-XTEN™ dual-masked T-cell engager; advancing oncology clinical pipeline with three ongoing Phase 1 studies Strong financial position and runway into mid-2027 with approximately $892.1 million in cash and investments as of June 30, 2025 Conference call scheduled for August 6, 2025 at... Read More

ECLIPSE registrational program now fully underway, following enrollment of the first patient in ECLIPSE 3 ECLIPSE 3 is designed to compare the combination of tobevibart and elebsiran to bulevirtide in patients with chronic hepatitis delta SAN FRANCISCO / Aug 06, 2025 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in ECLIPSE 3. All three trials in the Company’s... Read More

First patient enrolled in ECLIPSE 2 Phase 3 clinical trial evaluating the switch to the combination of tobevibart and elebsiran in patients not achieving undetectable hepatitis delta virus RNA despite bulevirtide treatment ECLIPSE 2 is a pivotal trial designed to support global marketing applications, including in the U.S. and Europe SAN FRANCISCO / Jul 31, 2025 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today... Read More

Phase 1 clinical trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5525 alone or in combination with pembrolizumab in a variety of EGFR-expressing solid tumors such as NSCLC, CRC, HNSCC and cSCC VIR-5525, the Company’s third dual-masked T-cell engager leveraging the PRO-XTEN™ technology, is designed to expand the therapeutic index by selectively activating in the tumor microenvironment... Read More

SAN FRANCISCO / Jul 22, 2025 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2025, on August 6, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on August 6, 2025. The corporate update and financial results will be provided via a press release shortly after... Read More

SAN FRANCISCO / May 28, 2025 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10 at 1:00 p.m. PT / 4:00 p.m. ET in Miami Beach, Florida. A live webcast of the fireside chat will be made available under Events &... Read More

SAN FRANCISCO / May 20, 2025 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, and Mika Kakefuda Derynck, M.D., Executive Vice President, Therapeutic Area Head, Oncology, will participate in a virtual fireside chat at the TD Cowen 6 th Annual Oncology Innovation Summit on Tuesday, May 27 at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast... Read More

SAN FRANCISCO / May 12, 2025 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14 at 1:40 p.m. PT / 4:40 p.m. ET in Las Vegas, Nevada. A live webcast of the fireside chat will be made available under Events &... Read More

HBsAg loss 24 weeks post-end of treatment achieved in 17% and 21% of participants with low baseline HBsAg receiving tobevibart + elebsiran without or with PEG-IFNα, respectively As previously announced, Phase 3 development in chronic hepatitis B to occur only with a global development and commercialization partner, which has not been secured Vir Biotechnology to streamline the final stages of MARCH Phase 2 study to ensure... Read More

Initiated Phase 3 registrational ECLIPSE program in chronic hepatitis delta with first patient enrolled in Q1 2025; Program received U.S. FDA Breakthrough and Fast Track designations and EMA PRIME and Orphan Drug designations Dose escalation continues for PRO-XTEN™ dual-masked T-cell engagers VIR-5818 (HER2) and VIR-5500 (PSMA) On track to initiate a Phase 1 study of VIR-5525, the PRO-XTEN™ dual-masked EGFR-targeting T-cell... Read More

SAN FRANCISCO / Apr 30, 2025 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2025, on May 7, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on May 7, 2025. The corporate update and financial results will be provided via a press release shortly after market... Read More

Phase 2 SOLSTICE subgroup analysis data in chronic hepatitis delta selected for poster presentation, and to be highlighted during EASL poster tour 24 Week post-treatment follow-up data in chronic hepatitis B from MARCH Phase 2 study to be shared in oral presentation SAN FRANCISCO / Apr 24, 2025 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from a 24-week subgroup... Read More

First patient enrolled in ECLIPSE 1 Phase 3 clinical trial evaluating combination of tobevibart and elebsiran for chronic suppressive treatment ECLIPSE program designed to enable regulatory submissions and support reimbursement and access Rapid study start indicative of significant unmet need for chronic hepatitis delta treatment SAN FRANCISCO / Mar 13, 2025 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today... Read More

Phase 3 ECLIPSE registrational clinical program in chronic hepatitis delta on track to begin in the first half of 2025 Tobevibart and elebsiran in chronic hepatitis delta received U.S. FDA Breakthrough and Fast Track designations and EMA PRIME and Orphan Drug designations Compelling early clinical response signals and promising safety profiles for dual-masked T-cell engagers VIR-5818 and VIR-5500 in heavily pretreated... Read More

SAN FRANCISCO / Feb 19, 2025 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the executive team are scheduled to participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4 at 8:50 a.m. PT / 11:50 a.m. ET in Boston, Massachusetts. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of... Read More

SAN FRANCISCO / Feb 12, 2025 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2024, on February 26, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on February 26, 2025. The corporate update and financial results will be provided via a press... Read More

Compelling early clinical response signals for VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors VIR-5818: In patients receiving doses ≥400 µg/kg, tumor shrinkage observed in 50% (10/20) of participants with various HER2-expressing cancers; confirmed partial responses in 33% (2/6) of participants with HER2-positive CRC VIR-5500: PSA declines in 100% (12/12) and PSA50 response confirmed in 58%... Read More

SAN FRANCISCO / Dec 18, 2024 / Business Wire / Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, at 4:30 p.m. PT in San Francisco, California. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir... Read More

Designations aim to expedite the development and review of promising therapies for serious conditions with unmet medical needs Phase 3 ECLIPSE registrational program in chronic hepatitis delta to begin in the first half of 2025 SAN FRANCISCO / Dec 12, 2024 / Business Wire / Vir Biotechnology, Inc . (Nasdaq: VIR) today announced that tobevibart and elebsiran have received U.S. Food and Drug Administration (FDA) Breakthrough... Read More

SAN FRANCISCO / Nov 26, 2024 / Business Wire / Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will host a virtual investor event to discuss initial data from the dual-masked Phase 1 T-cell engagers VIR-5818 targeting a variety of HER2-expressing solid tumors and VIR-5500 targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC) along with updates on the PRO-XTEN™ platform on January 8, 2025, at 5:00... Read More

SAN FRANCISCO / Nov 25, 2024 / Business Wire / Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday December 3, at 6:10 a.m. PT / 9:10 a.m. ET in Miami, Florida. A live webcast of the fireside chat will be made available under Events &... Read More

Monthly tobevibart and elebsiran combination achieves rapid 100% virologic suppression at Week 24, sustained through Week 60 Undetectable HDV RNA in 41% of participants at Week 24, increasing to 64% by Week 36 and up to 80% by Week 60 across cohorts Combination well-tolerated: no treatment-related severe AEs, treatment-related discontinuations or ALT flares Following a recent FDA meeting, Phase 3 ECLIPSE registrational... Read More

Orphan designation in E.U. supports development of treatments for life-threatening or chronically debilitating conditions with significant unmet medical need Phase 2 SOLSTICE 24-week primary endpoint data for tobevibart and elebsiran in chronic hepatitis delta to be presented today at AASLD The Liver Meeting Positive opinion on E.U. orphan drug designation follows U.S. FDA fast track designation, highlighting growing... Read More

39% of participants with low baseline Hepatitis B surface antigen (HBsAg) achieved HBsAg loss with tobevibart + elebsiran, and 46% with tobevibart + elebsiran + pegylated interferon alfa No new safety concerns were identified, and treatment-emergent adverse events were generally mild to moderate Late-breaking oral presentation of MARCH Part B study results at the American Association for the Study of Liver Diseases (AASLD)... Read More

Successful closing of exclusive worldwide licensing agreement with Sanofi for three potential best-in-class clinical-stage dual-masked T-cell engagers with initial clinical data anticipated in Q1 2025 Key Phase 2 SOLSTICE data in chronic hepatitis delta to be presented at AASLD 2024 The Company will host a Hepatitis Investor Event following AASLD on November 19, 2024 Jason O’Byrne appointed as Chief Financial Officer... Read More

SAN FRANCISCO / Oct 17, 2024 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2024, on October 31, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on October 31, 2024. The corporate update and financial results will be provided via a press... Read More

Phase 2 SOLSTICE Safety and Efficacy Data in Hepatitis Delta Trial at Week 24 to Be Presented Oral and Five Poster Presentations Highlight Important Progress in Hepatitis Delta and Hepatitis B Clinical Programs, and Deliver Key Insights on the Burden of Disease Among Patient Segments in Hepatitis Delta SAN FRANCISCO / Oct 15, 2024 / Business Wire / Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will present new data... Read More

SAN FRANCISCO / Oct 03, 2024 / Business Wire / Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer, is scheduled to participate in a fireside chat at the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference on Tuesday, October 8, at 10:00 a.m. PT / 1:00 p.m. ET. A live webcast of the fireside chat will be made available under Events... Read More

Seasoned biotech executive brings decades of effective financial leadership to Vir SAN FRANCISCO / Sep 10, 2024 / Business Wire / Vir Biotechnology Inc. (Nasdaq: VIR) today announced that Jason O’Byrne, MBA, is appointed as Executive Vice President and Chief Financial Officer (CFO), effective October 2, 2024. Mr. O’Byrne will join the Vir Executive Management Team and report directly to the company’s Chief Executive Officer,... Read More

License of proprietary masking platform further strengthens Vir’s drug discovery capabilities in oncology and infectious disease Strategic agreement expands Vir portfolio with three clinical stage assets in areas of high unmet need SAN FRANCISCO / Sep 09, 2024 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the exclusive worldwide license agreement with Sanofi announced on August 1, 2024, has... Read More

SAN FRANCISCO / Aug 22, 2024 / Business Wire / Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the Morgan Stanley 22 nd Annual Global Healthcare Conference on Thursday, September 5, at 1:50 p.m. PT / 4:50 p.m. ET in New York City. A live webcast of the fireside chat will be made available under Events &... Read More

Positive preliminary Phase 2 chronic hepatitis delta study data presented at EASL™ Congress 2024, FDA IND clearance with Fast Track Designation received underscoring the potential of combination therapy Exclusive license agreement with Sanofi bolsters clinical pipeline Strategic workforce restructuring and phasing out of influenza, COVID-19, and the Company’s T cell-based viral vector platform programs $1.43 billion in cash,... Read More

Bolsters clinical pipeline and adds near-term value creation opportunities Licenses proprietary masking platform with goal of minimizing off-tumor toxicity and offering expanded therapeutic index in patients Strategic deal highly synergistic with Vir’s mAb engineering platform and T-cell biology expertise SAN FRANCISCO / Aug 01, 2024 / Business Wire / Vir Biotechnology, Inc . (Nasdaq: VIR) today announced that it has entered... Read More

SAN FRANCISCO / Jul 18, 2024 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2024. Financial results will be provided via a press release after market close and will be accessible under Press... Read More

Fast Track designation follows positive preliminary Phase 2 trial data presented at the European Association for the Study of the Liver Congress 2024 and underscores the unmet need for people living with chronic hepatitis delta SAN FRANCISCO / Jun 26, 2024 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND)... Read More

Preliminary Phase 2 SOLSTICE trial data reinforce the potential of both regimens to be transformative treatments in an area of high unmet medical need Conference call scheduled for June 5, 2024, at 6:00 a.m. ET / 12:00 p.m. CEST SAN FRANCISCO / Jun 05, 2024 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new preliminary data from its Phase 2 SOLSTICE hepatitis delta clinical trial evaluating... Read More

SAN FRANCISCO / May 29, 2024 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the Goldman Sachs 45 th Annual Global Healthcare Conference on Wednesday, June 12, at 11:00 a.m. PT / 2:00 p.m. ET at the Loews Miami Beach Hotel, Miami Beach, Florida. A live webcast of the fireside chat will... Read More

Exceptional biotech executive brings more than 32 years of leadership to Vir Deep knowledge in immunology and infectious disease with proven track record of bringing late-stage clinical development candidates into market SAN FRANCISCO / May 29, 2024 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Mark D. Eisner, M.D., M.P.H. will join the company as Executive Vice President and Chief Medical... Read More

SAN FRANCISCO / May 23, 2024 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2024 Annual Meeting of Stockholders on Wednesday, May 29, 2024, at 9:00 a.m. PT. The Annual Meeting will be held in virtual format only via live audio webcast. Vir Biotechnology’s stockholders of record at the close of business on April 1, 2024, the record date for the Annual Meeting, can... Read More

Company to present important new data from the Phase 2 SOLSTICE chronic hepatitis delta trial Conference call scheduled for June 5, 2024, at 6:00 a.m. ET / 12:00 p.m. CEST SAN FRANCISCO / May 22, 2024 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting new data from the Company’s chronic hepatitis delta and chronic hepatitis B programs have been accepted for presentation... Read More

SAN FRANCISCO / May 21, 2024 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the EASL Congress has changed the Company’s Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker poster to an oral presentation. The SOLSTICE data will be presented on June 8 during the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2024, taking place in Milan, Italy, June... Read More

Late-breaker SOLSTICE data abstract accepted for poster presentation at the European Association for the Study of the Liver (EASL) Congress 2024 Two additional hepatitis program data readouts on track for the fourth quarter 2024 $1.51 billion in cash, cash equivalents and investments as of March 31, 2024 Conference call scheduled for May 2, 2024 at 1:30 p.m. PT / 4:30 p.m. ET SAN FRANCISCO / May 02, 2024 / Business Wire /... Read More

SAN FRANCISCO / Apr 30, 2024 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the BofA Securities Healthcare Conference 2024 on Tuesday, May 14, at 4:20 p.m. PT / 7:20 p.m. ET. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors... Read More

SAN FRANCISCO / Apr 18, 2024 / Business Wire / Vir Biotechnology, Inc. (“Vir” or “the Company”, Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (the “Board”) at its upcoming annual meeting of stockholders on May 29, 2024 (the “Annual Meeting”). If elected, each of Drs. Bischofberger and Farid will join the Board on such date. The nomination of the... Read More

SAN FRANCISCO / Apr 11, 2024 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 2, 2024. The corporate update and financial results will be provided via a press release after... Read More

Over 60 participants dosed in two additional cohorts; initial data expected in the second quarter Approximately 50% of participants have compensated cirrhosis SAN FRANCISCO / Mar 05, 2024 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic... Read More

SAN FRANCISCO / Feb 23, 2024 / Business Wire / Vir Biotechnology, Inc. ( Nasdaq: VIR) today announced that management will be participating in the following upcoming investor conferences during the month of March: TD Cowen 44th Annual Health Care Conference at the Boston Marriott Copley Place in Boston. Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat on Monday,... Read More

Prior data from the Phase 2 SOLSTICE trial in chronic hepatitis delta participants demonstrated that after only 12 weeks of combination therapy, 100% (6/6) of participants had HDV RNA less than the lower limit of quantification Phase 2 SOLSTICE trial on track to complete enrollment ahead of schedule with initial data expected in the second quarter; greater than 90% of participants dosed Prior Phase 2 MARCH Part B chronic... Read More

SAN FRANCISCO / Feb 20, 2024 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Executive Vice President, and Chief Medical Officer, Phil Pang, M.D., Ph.D., has decided to leave the company at the end of March 2024 to spend more time with his family. The Company has initiated a search for a successor. “Phil has served as a formidable leader at Vir, where he played a major part in the development of... Read More

SAN FRANCISCO / Feb 01, 2024 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter ended December 31, 2023, on February 22, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on February 22, 2024. The corporate update and financial results will be provided via a press... Read More

Reinforcing strategic focus on chronic hepatitis delta and chronic hepatitis B clinical programs and antibody platform to target infectious diseases, autoimmune diseases, and oncology Reducing workforce by approximately 12% and consolidating geographic footprint Anticipate annual savings of at least $40 million from cost optimization efforts SAN FRANCISCO / Dec 13, 2023 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR)... Read More

SAN FRANCISCO / Dec 06, 2023 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chief Executive Officer, will present at the J.P. Morgan 2024 42 nd Annual Healthcare Conference on Wednesday, January 10, at 3:45 p.m. PT / 6:45 p.m. ET. A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir... Read More

Initial SOLSTICE data suggests the potential of VIR-3434 + VIR-2218 to address the unmet need for a highly efficacious hepatitis delta therapy New MARCH Part B data demonstrate that VIR-3434 may play an important role in achieving a functional cure for chronic hepatitis B Conference call scheduled for 1:45 p.m. PT / 4:45 p.m. ET, November 13, 2023 SAN FRANCISCO / Nov 13, 2023 / Business Wire / Vir Biotechnology, Inc.... Read More

SAN FRANCISCO / Nov 10, 2023 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 and VIR-2218 could have for chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) patients at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting ® , taking place in Boston,... Read More

SAN FRANCISCO / Nov 08, 2023 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it ranked first for the second year in a row on the 2023 Deloitte Technology Fast 500 ™ , a list of the fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech companies in North America. This is the first time in the 29-year history of the Deloitte Technology Fast 500 program that a... Read More

Company to present new data at AASLD from Phase 2 chronic hepatitis B and chronic hepatitis delta clinical trials Company expanding strategic focus to autoimmune diseases and immuno-oncology Jennifer Towne, Ph.D., appointed as Executive Vice President and Chief Scientific Officer, effective November 6, 2023 Secured new BARDA funding for the development of RNA-delivered monoclonal antibodies $1.7 billion in cash, cash... Read More

SAN FRANCISCO / Oct 30, 2023 / Business Wire / Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer, effective November 6, 2023. Dr. Towne will be responsible for leading the Company’s research function from basic research through scale-up manufacturing and the introduction of drug candidates to clinical trials. She will... Read More

SAN FRANCISCO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Vir’s Executive Vice President, Chief Medical Officer and Interim Head of Research, is participating in a virtual fireside Q&A at the H.C. Wainwright 4 th Annual Hepatitis B Virus (HBV) Conference on Wednesday, October 25, at 7:00 a.m. PT / 10:00 a.m. ET. A live webcast of the fireside chat can... Read More

SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that eight abstracts highlighting new data from its chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) clinical programs have been accepted for presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting ® , taking place in Boston, MA, from November 10-14, 2023. These include... Read More

SAN FRANCISCO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2023, on November 2, 2023. The Company will host a conference call at 4:30 p.m. Eastern Time on November 2, 2023. The corporate update and financial results will be provided via a press release after market... Read More

New investment of approximately $50 million from Biomedical Advanced Research and Development Authority includes $40 million in Project NextGen funds Contract expands existing support for the development of candidates for prevention and treatment of pathogens of pandemic potential SAN FRANCISCO, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Biomedical Advanced Research and... Read More

Based on a novel human cytomegalovirus vector platform, VIR-1388 was designed with the goal of creating a novel HIV vaccine Phase 1 trial supported by the Bill & Melinda Gates Foundation, the National Institute of Allergy and Infectious Diseases and conducted by the HIV Vaccine Trials Network SAN FRANCISCO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first participant has... Read More

SAN FRANCISCO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that management will be participating in the following upcoming investor conferences during the month of September: Morgan Stanley 21 st Annual Global Healthcare Conference at the Sheraton New York Times Square Hotel in New York. Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in... Read More

Phase 2 data readouts from ongoing chronic hepatitis B and chronic hepatitis delta programs on track for Q4 2023 Increased focus on proprietary antibody platform and discontinuation of Vir’s innate immunity small molecule platform First participant to be dosed in Phase 1 trial of next-generation HIV vaccine, VIR-1388, anticipated in Q3 $1.9 billion in cash, cash equivalents and investments as of June 30, 2023 Conference call... Read More

SAN FRANCISCO, July 26, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2023 on August 3, 2023. The Company will host a conference call at 4:30 p.m. Eastern Time on August 3, 2023. The corporate update and financial results will be provided via a press release after market close and... Read More

SAN FRANCISCO, July 20, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Phase 2 PENINSULA ( P rev E ntio N of I ll N es S D U e to Inf L uenza A ) trial evaluating VIR-2482 for the prevention of symptomatic influenza A illness did not meet primary or secondary efficacy endpoints. In participants who received the highest dose of VIR-2482 (1,200 mg), a non-statistically significant... Read More

SAN FRANCISCO, June 29, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer, effective July 10, 2023. Ms. Damouni Ellis will be responsible for the Company’s strategic approach to corporate communications, government affairs, investor relations and patient advocacy, as well as for establishing... Read More

Data from two ongoing clinical trials in people living with chronic hepatitis B infection suggest the combination of an antiviral with an immunomodulator can achieve rapid and deep declines in hepatitis B virus surface antigen (HBsAg) and higher rates of HBsAg loss compared to antivirals or immunomodulators alone Preclinical data suggest the potential of VIR-2218 and VIR-3434 as treatment for the chronic suppression of... Read More

SAN FRANCISCO, June 07, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that five abstracts highlighting new data from the Company’s broad hepatitis portfolio addressing both hepatitis B virus (HBV) and hepatitis D virus (HDV) have been accepted for presentation at the annual meeting of the European Association for the Study of the Liver, EASL ™ Congress 2023, taking place in Vienna from June... Read More

SAN FRANCISCO, June 05, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat at the 44 th Annual Goldman Sachs Global Healthcare Conference on Monday, June 12, at 10:40 a.m. PT / 1:40 p.m. ET. A live webcast of the presentation can be accessed under Events & Presentations in the... Read More

SAN FRANCISCO, May 17, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2023 Annual General Meeting of Stockholders on Friday, May 19, 2023, at 11:30 a.m. PT. The Annual Meeting will be held in virtual format only via live audio webcast. Vir Biotechnology’s stockholders of record as of March 30, 2023 (the “Record Date”) can attend and vote at the Annual Meeting... Read More

SAN FRANCISCO, May 15, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc . (Nasdaq: VIR) today announced the appointment of Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer. Dr. Calcagno will be responsible for leading the Company’s business development efforts, optimizing existing alliances and establishing new strategic industry and public-private partnerships. He reports to Vir’s Chief Executive... Read More

STRIVE is the first Phase 2 sub-protocol trial initiated under Vir’s new PREVAIL platform trial investigating the Company’s novel therapies in two chronic hepatitis B virus patient populations SAN FRANCISCO, May 11, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first participant has been dosed in the Phase 2 STRIVE sub-protocol clinical trial evaluating the safety and efficacy of... Read More

Multiple data readouts anticipated in 2023 from ongoing Phase 2 programs in hepatitis B and D, and influenza Industry veteran Dr. Marianne De Backer assumes CEO position prepared to lead Company through next phase of growth $2.3 billion in cash, cash equivalents, and investments as of March 31, 2023 SAN FRANCISCO, May 04, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and... Read More

SAN FRANCISCO, May 03, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to present at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, at 8:00 a.m. PT / 11:00 a.m. ET. A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at... Read More

New grant from the Bill & Melinda Gates Foundation supports the Phase 1 development of VIR-1388, an investigational HIV T cell vaccine based on a novel vector Long-standing partnership further advances research for the prevention and treatment of global infectious diseases SAN FRANCISCO, May 02, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it received a new $10 million grant from the... Read More

SAN FRANCISCO, April 11, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head of Research, is scheduled to participate in a fireside chat at the 22 nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, at 12:00 p.m. PT / 3:00 p.m. ET. A live webcast of the presentation can be accessed under... Read More

SAN FRANCISCO, March 08, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head of Research, is scheduled to present at the Barclays Global Healthcare Conference on Wednesday, March 15, at 7:15 a.m. PT / 10:15 a.m. ET. A live webcast of the presentation can be accessed under Events & Presentations in the... Read More

SAN FRANCISCO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Bolyn Hubby, Ph.D., Executive Vice President and Chief Corporate Affairs Officer, will participate in a panel focused on infectious diseases at the Cowen 43 rd Annual Health Care Conference on Tuesday, March 7, at 6:10 a.m. PT / 9:10 a.m. ET. A live webcast of the panel can be accessed under Events & Presentations in... Read More

Transformational year ahead with critical Phase 2 readouts expected for programs in hepatitis B, hepatitis D and influenza with the potential for significant patient impact $1.5 billion of sotrovimab collaboration revenue recognized in 2022 Strong balance sheet expected to fund Vir’s robust portfolio through major inflection points with the flexibility to evaluate external opportunities SAN FRANCISCO, Feb. 23, 2023 (GLOBE... Read More

SAN FRANCISCO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the UK’s National Institute for Health and Care Excellence (NICE) provided positive final draft guidance recommending the use of sotrovimab, an investigational SARS-CoV-2 neutralizing monoclonal antibody, in adults who do not need supplemental oxygen for COVID-19 and who have an increased risk for progression to severe... Read More

SAN FRANCISCO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2022, on Thursday, February 23, 2023. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the... Read More

Experienced biotech executive brings more than 20 years of financial leadership to Vir Howard Horn departing to pursue next chapter; will remain in an advisory role through a brief transition period SAN FRANCISCO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sung Lee as Executive Vice President and Chief Financial Officer (CFO), effective March 27, 2023. The... Read More

Vir to continue advancing next-generation COVID-19 solutions independently or with other partners The Companies will continue working together to ensure ongoing access to sotrovimab for patients around the world, where authorized, and to advance new therapies for influenza and other respiratory diseases SAN FRANCISCO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the research... Read More

Dr. De Backer to assume CEO role on April 3, 2023 Upon his retirement as CEO, Dr. Scangos will transition to an advisory role through June 2, 2023 and will continue providing strategic counsel to Vir as a member of the Board of Directors SAN FRANCISCO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., will retire from his position as Chief Executive Officer... Read More

Critical Phase 2 readouts anticipated in 2023 for three advanced programs – hepatitis B, hepatitis D and influenza Strong balance sheet expected to fund Vir’s robust portfolio through major inflection points with the flexibility to evaluate external opportunities SAN FRANCISCO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will... Read More

SAN FRANCISCO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it has achieved the target enrollment of approximately 3,000 participants in the groundbreaking Phase 2 PENINSULA ( P rev E ntio N of I ll N es S D U e to Inf L uenza A ) trial evaluating VIR-2482 for the prevention of illness due to influenza A. PENINSULA is the first Phase 2 outpatient trial to evaluate the role of a... Read More